118 related articles for article (PubMed ID: 21495229)
1. Molecular characteristics and risk factors in endometrial cancer: what are the treatment and preventative strategies?
Ellis PE; Ghaem-Maghami S
Int J Gynecol Cancer; 2010 Oct; 20(7):1207-16. PubMed ID: 21495229
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapeutic targets in endometrial cancer.
Dedes KJ; Wetterskog D; Ashworth A; Kaye SB; Reis-Filho JS
Nat Rev Clin Oncol; 2011 May; 8(5):261-71. PubMed ID: 21221135
[TBL] [Abstract][Full Text] [Related]
3. Endometrial cancer: molecular and therapeutic aspects.
Tsikouras P; Bouchlariotou S; Vrachnis N; Dafopoulos A; Galazios G; Csorba R; von Tempelhoff GF
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(1):1-9. PubMed ID: 23433742
[TBL] [Abstract][Full Text] [Related]
4. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.
Bansal N; Yendluri V; Wenham RM
Cancer Control; 2009 Jan; 16(1):8-13. PubMed ID: 19078924
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mTOR/4E-BP pathway in endometrial cancer.
Korets SB; Czok S; Blank SV; Curtin JP; Schneider RJ
Clin Cancer Res; 2011 Dec; 17(24):7518-28. PubMed ID: 22142830
[TBL] [Abstract][Full Text] [Related]
7. Single nucleotide polymorphism: a new risk factor for endometrial cancer?
Kang S; Roh JW; Kim JW
Future Oncol; 2005 Jun; 1(3):323-30. PubMed ID: 16556006
[TBL] [Abstract][Full Text] [Related]
8. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Chen J; Zhao KN; Li R; Shao R; Chen C
Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
Husseinzadeh N; Husseinzadeh HD
Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer.
Shafiee MN; Seedhouse C; Mongan N; Chapman C; Deen S; Abu J; Atiomo W
Mol Cell Endocrinol; 2016 Mar; 424():94-101. PubMed ID: 26802879
[TBL] [Abstract][Full Text] [Related]
11. Endometrial carcinoma tumorigenesis and pharmacotherapy research.
Shu J; Fang S; Teichman PG; Xing L; Huang H
Minerva Endocrinol; 2012 Jun; 37(2):117-32. PubMed ID: 22691886
[TBL] [Abstract][Full Text] [Related]
12. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
14. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
15. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer.
Barra F; Evangelisti G; Ferro Desideri L; Di Domenico S; Ferraioli D; Vellone VG; De Cian F; Ferrero S
Expert Opin Investig Drugs; 2019 Feb; 28(2):131-142. PubMed ID: 30574817
[TBL] [Abstract][Full Text] [Related]
16. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies for endometrial cancer: current practice and perspective.
Lee YC; Lheureux S; Oza AM
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):47-58. PubMed ID: 27941361
[TBL] [Abstract][Full Text] [Related]
18. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.
Risinger JI; Hayes K; Maxwell GL; Carney ME; Dodge RK; Barrett JC; Berchuck A
Clin Cancer Res; 1998 Dec; 4(12):3005-10. PubMed ID: 9865913
[TBL] [Abstract][Full Text] [Related]
19. Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review.
Tinelli A; Vergara D; Martignago R; Leo G; Malvasi A; Tinelli R
Acta Obstet Gynecol Scand; 2008; 87(11):1101-13. PubMed ID: 18607816
[TBL] [Abstract][Full Text] [Related]
20. Molecular targets and targeted therapeutics in endometrial cancer.
Weigelt B; Banerjee S
Curr Opin Oncol; 2012 Sep; 24(5):554-63. PubMed ID: 22581357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
